|
1
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014:1491852014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirra J: Bone Tumors: Clinical,
radiologic, and pathologic correlations. Lea and Febiger;
Philadelphia, PA: 1989
|
|
3
|
Galoian K, Scully S, McNamara G, Flynn P
and Galoyan A: Antitumorigenic effect of brain proline rich
polypeptide-1 in human chondrosarcoma. Neurochem Res. 34:2117–2121.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galoian K, Scully S and Galoyan A:
Myc-oncogene inactivating effect by proline rich polypeptide
(PRP-1) in chondrosarcoma JJ012 cells. Neurochem Res. 34:379–385.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galoian K, Temple HT and Galoyan A:
Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by
mTOR and cMyc inhibition in high grade chondrosarcoma. Neurochem
Res. 36:812–818. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galoian KA, Temple HT and Galoyan A:
Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in
MDA231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal
tumors. Tumour Biol. 32:745–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Galoian K, Temple HT and Galoyan A: mTORC1
inhibition and ECM-cell adhesion-independent drug resistance via
Pl3K-AKT and Pl3K-RAS-MAPK feedback loops. Tumour Biol. 33:885–90.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galoian K, Qureshi A, D'ippolito G,
Schiller PC, Molinari M, Johnstone AL, Brothers SP, Paz AC and
Temple HT: Epigenetic regulation of embryonic stem cell marker
miR302C in human chondrosarcoma as determinant of antiproliferative
activity of proline-rich polypeptide 1. Int J Oncol. 47:465–472.
2015.PubMed/NCBI
|
|
9
|
Galoian K, Qureshi A, Wideroff G and
Temple HT: Restoration of desmosomal junction protein expression
and inhibition of H3K9-specific histone demethylase activity by
cytostatic proline-rich polypeptide-1 leads to suppression of
tumorigenic potential in human chondrosarcoma cells. Mol Clin
Oncol. 3:171–178. 2015.PubMed/NCBI
|
|
10
|
Galoian K, Guettouche T, Issac B, Qureshi
A and Temple HT: Regulation of onco and tumor suppressor miRNAs by
mTORC 1 inhibitor PRP-1 in human chondrosarcoma. Tumour Biol.
35:2335–2341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu
J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is
associated with decrease of TET gene expression and
5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q,
Ding J, Jia Y, Chen Z, Li L, et al: Tet-mediated formation of
5-carboxylcytosine and its excision by TDG in mammalian DNA.
Science. 333:1303–1307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ito S, Shen L, Dai Q, Wu SC, Collins LB,
Swenberg JA, He C and Zhang Y: Tet proteins can convert
5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine.
Science. 333:1300–1303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chmielecki J and Meyerson M: DNA
sequencing of cancer: What have we learned? Annu Rev Med. 65:63–79.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim
SH, Ito S, Yang C, Wang P, Xiao MT, et al: Oncometabolite
2-hydroxyglutarate is a competitive inhibitor of
α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tahiliani M, Koh KP, Shen Y, Pastor WA,
Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and
Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suijker J, Oosting J, Koornneef A, Struys
EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM,
Briaire-de Bruijn IH, Haazen L, et al: Inhibition of mutant IDH1
decreases D-2-HG levels without affecting tumorigenic properties of
chondrosarcoma cell lines. Oncotarget. 6:12505–12519. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haseeb A, Makki MS and Haqqi TM:
Modulation of ten-eleven translocation 1 (TET1), Isocitrate
Dehydrogenase (IDH) expression, α-Ketoglutarate (α-KG), and DNA
hydroxymethylation levels by interleukin-1β in primary human
chondrocytes. J Biol Chem. 289:6877–6885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deel MD, Li JJ, Crose LE and Linardic CM:
A review: Molecular aberrations within hippo signaling in bone and
soft-tissue sarcomas. Front Oncol. 5:1902015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tiet TD, Hopyan S, Nadesan P, Gokgoz N,
Poon R, Lin AC, Yan T, Andrulis IL, Alman BA and Wunder JS:
Constitutive hedgehog signaling in chondrosarcoma up-regulates
tumor cell proliferation. Am J Pathol. 168:321–30. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu
Q, Wang Y, Halder G, Finegold MJ, Lee JS and Johnson RL: Hippo
signaling is a potent in vivo growth and tumor suppressor pathway
in the mammalian liver. Proc Natl Acad Sci USA. 107:1437–1442.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisinger-Mathason TS, Mucaj V, Biju KM,
Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S
and Simon MC: Deregulation of the Hippo pathway in soft-tissue
sarcoma promotes FOXM1 expression and tumorigenesis. Proc Natl Acad
Sci USA. 112:E3402–E3411. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mohamed AD, Tremblay AM, Murray GI and
Wackerhage H: The Hippo signal transduction pathway in soft tissue
sarcomas. Biochim Biophys Acta. 1856:121–129. 2015.PubMed/NCBI
|
|
24
|
Li R, Cai L, Ding J, Hu CM, Wu TN and Hu
XY: Inhibition of hedgehog signal pathway by cyclopamine attenuates
inflammation and articular cartilage damage in rats with
adjuvant-induced arthritis. J Pharm Pharmacol. 67:963–971. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakashima H, Nakamura M, Yamaguchi H,
Yamanaka N, Akiyoshi T, Koga K, Yamaguchi K, Tsuneyoshi M, Tanaka M
and Katano M: Nuclear factor-kappaB contributes to hedgehog
signaling pathway activation through sonic hedgehog induction in
pancreatic cancer. Cancer Res. 66:7041–7049. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zacharias WJ, Li X, Madison BB, Kretovich
K, Kao JY, Merchant JL and Gumucio DL: Hedgehog is an
anti-inflammatory epithelial signal for the intestinal lamina
propria. Gastroenterology. 138:2368–2377, 2377.e1-e4. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taniguchi K, Wu LW, Grivennikov SI, de
Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, et al:
A gp130-Src-YAP module links inflammation to epithelial
regeneration. Nature. 519:57–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duh QY and Grossman RF: Thyroid growth
factors, signal transduction pathways, and oncogenes. Surg Clin
North Am. 75:421–437. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barclay JL, Anderson ST, Waters MJ and
Curlewis JD: SOCS3 as a tumor suppressor in breast cancer cells,
and its regulation by PRL. Int J Cancer. 124:1756–1766. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Revel M: Growth regulatory functions of
IL6 and antitumor effects. Res Immunol. 143:769–773. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Givon T, Slavin S, Haran-Ghera N,
Michalevicz R and Revel M: Antitumor effects of human recombinant
interleukin-6 on acute myeloid leukemia in mice and in cell
cultures. Blood. 79:2392–2398. 1992.PubMed/NCBI
|
|
32
|
Basolo F, Fiore L, Pollina L, Fontanini G,
Conaldi PG and Toniolo A: Reduced expression of interleukin 6 in
undifferentiated thyroid carcinoma: in vitro and in vivo studies.
Clin Cancer Res. 4:381–387. 1998.PubMed/NCBI
|
|
33
|
Mulé JJ, McIntosh JK, Jablons DM and
Rosenberg SA: Antitumor activity of recombinant interleukin 6 in
mice. J Exp Med. 171:629–636. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ragazzi M, Ciarrocchi A, Sancisi V,
Gandolfi G, Bisagni A and Piana S: Update on anaplastic thyroid
carcinoma: Morphological, molecular, and genetic features of the
most aggressive thyroid cancer. Int J Endocrinol. 2014:7908342014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tseleni-Balafouta S, Arvanitis D,
Kakaviatos N and Paraskevakou H: Primary myxoid chondrosarcoma of
the thyroid gland. Arch Pathol Lab Med. 112:94–96. 1988.PubMed/NCBI
|
|
36
|
Galoian K, Guettouche T, Issac B, Navarro
L and Temple HT: Lost miRNA surveillance of Notch, IGFR
pathway-road to sarcomagenesis. Tumour Biol. 35:483–492. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sarkar S, Horn G, Moulton K, Oza A, Byler
S, Kokolus S and Longacre M: Cancer development, progression, and
therapy: An epigenetic overview. Int J Mol Sci. 14:21087–21113.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lian CG, Xu Y, Ceol C, Wu F, Larson A,
Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al: Loss of
5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
Cell. 150:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fan M, He X and Xu X: Restored expression
levels of TET1 decrease the proliferation and migration of renal
carcinoma cells. Mol Med Rep. 12:4837–4842. 2015.PubMed/NCBI
|
|
40
|
Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap
YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H,
Lobry C, et al: TET1 is a tumor suppressor of hematopoietic
malignancy. Nat Immunol. 16:8892015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li
X, Zhao D, Liu Y, Wang C, Zhang X, et al: Tet2 is required to
resolve inflammation by recruiting Hdac2 to specifically repress
IL-6. Nature. 525:389–393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jo D, Liu D, Yao S, Collins RD and Hawiger
J: Intracellular protein therapy with SOCS3 inhibits inflammation
and apoptosis. Nat Med. 11:892–898. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qin H, Holdbrooks AT, Liu Y, Reynolds SL,
Yanagisawa LL and Benveniste EN: SOCS3 deficiency promotes M1
macrophage polarization and inflammation. J Immunol. 189:3439–3448.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Villeneuve LM, Reddy MA, Lanting LL, Wang
M, Meng L and Natarajan R: Epigenetic histone H3 lysine 9
methylation in metabolic memory and inflammatory phenotype of
vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA.
105:9047–9052. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Blanchard F, Duplomb L, Baud'huin M and
Brounais B: The dual role of IL-6-type cytokines on bone remodeling
and bone tumors. Cytokine Growth Factor Rev. 20:19–28. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Clark JC, Akiyama T, Dass CR and Choong
PF: New clinically relevant, orthotopic mouse models of human
chondrosarcoma with spontaneous metastasis. Cancer Cell Int.
10:202010. View Article : Google Scholar : PubMed/NCBI
|
